Study: Fewer Severe Strokes With Rivaroxaban than Warfarin in Non-Valvular Afib Patients – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Findings presented at the 2018 American Heart Association meeting demonstrated that non-valvular atrial fibrillation (AFib) patients taking rivaroxaban (Xarelto, Jannsen) had a lower risk of stroke when compared to patients taking warfarin.
According to the results of a retrospective study that included 6,876 and 13,597 patients initiated on rivaroxaban or warfarin respectively, who were de-identified from the Optum Clinformatics® Database (2011-2017), the rivaroxaban cohort “had a significantly lower risk of 27% for stroke across all stroke severities (HR=0.63, P<.01); specifically, a 62% lower risk (HR = 0.38, p=0.03) for more severe stroke (NIHSS ≥16). The rivaroxaban cohort was associated with 64% lower risk (HR=0.36, P<.01) for 30-day post-stroke mortality relative to the warfarin cohort,” according to the study abstract.